• Molecular NameEntecavir
  • Synonymentecavir
  • Weight277.284
  • Drugbank_IDDB00442
  • ACS_NO142217-69-4
  • Show 3D model
  • LogP (experiment)-0.8
  • LogP (predicted, AB/LogP v2.0)-0.4
  • pkaN/A
  • LogD (pH=7, predicted)-0.4
  • Solubility (experiment)2.4 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.48
  • LogSw (predicted, AB/LogsW2.0)1.14
  • Sw (mg/ml) (predicted, ACD/Labs)0.92
  • No.of HBond Donors5
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds2
  • TPSA125.76
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn oral antiviral drug used in the treatment of hepatitis B infection.
  • Absorption_value100.0
  • Absorption (description)Absorption Following oral administration in healthy subjects, entecavir peak plasma concentrations occurred between 0.5 and 1.5 hours. In healthy subjects, the bioavailability of the tablet is 100% relative to the oral solution.
  • Caco_2N/A
  • Bioavailability100.0
  • Protein binding13.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life128~149 h
  • ExcretionRenal 62~73%
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most common adverse events possibly related to Baraclude were headache, fatigue, dizziness, and nausea.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A